Immuneering (IMRX) Cash from Operations (2020 - 2024)
Immuneering has reported Cash from Operations over the past 5 years, most recently at 14510513.0 for Q4 2024.
- Quarterly results put Cash from Operations at 14510513.0 for Q4 2024, down 23.23% from a year ago — trailing twelve months through Dec 2024 was 54999571.0 (down 12.32% YoY), and the annual figure for FY2025 was 45344595.0, up 17.55%.
- Cash from Operations for Q4 2024 was 14510513.0 at Immuneering, down from 13472024.0 in the prior quarter.
- Over the last five years, Cash from Operations for IMRX hit a ceiling of 3486028.0 in Q3 2020 and a floor of 15491114.0 in Q1 2024.
- Median Cash from Operations over the past 5 years was 11137201.5 (2023), compared with a mean of 10436638.67.
- Biggest five-year swings in Cash from Operations: plummeted 159.17% in 2021 and later fell 0.23% in 2023.
- Immuneering's Cash from Operations stood at 5453116.0 in 2020, then plummeted by 69.43% to 9238990.0 in 2021, then dropped by 27.16% to 11748614.0 in 2022, then decreased by 0.23% to 11775201.0 in 2023, then fell by 23.23% to 14510513.0 in 2024.
- The last three reported values for Cash from Operations were 14510513.0 (Q4 2024), 13472024.0 (Q3 2024), and 11525920.0 (Q2 2024) per Business Quant data.